Bone morphogenetic protein-7 (BMP-7) affects the presence of macrophage subtypes in vitro and in vivo at an early stage of atherosclerosis (ATH); however, it remains unknown whether BMP-7 treatment affects the development and progression of ATH at a midstage of the disease. We therefore performed a Day 28 (D28) study to examine BMP-7's potential to affect monocyte differentiation. Atherosclerosis was developed in ApoE KO mice, and these animals were treated with intravenous injections of BMP-7 and/or liposomal clodronate (LC). BMP-7 significantly (P < 0.05) lowers plaque formation following induction of atherosclerosis. However, upon macrophage depletion, BMP-7 fails to significantly alter plaque progression suggesting a direct role of BMP-7 on macrophages. Immunohistochemical staining of carotid arteries was performed to determine BMP-7's effect on pro-inflammatory M1 inducible nitric oxide synthase and anti-inflammatory M2 (cluster of differentiation [CD]206, Arginase-1) macrophages, and monocytes ( CD14). BMP-7 significantly reduced pro-inflammatory M1 macrophages and increased antiinflammatory M2 macrophages at D28, while BMP-7 showed no effect on M2 macrophage differentiation in animals treated with LC. Enzyme-linked immunosorbent assay data showed significant reduction in proinflammatory cytokines (Interleukin-6 [IL-6]), monocyte chemoattractant protein-1, and tumor necrosis factor-a) and a significant increase in anti-inflammatory cytokine (IL-10) in BMP-7 treated mice (P < 0.05).Western blot analysis of arterial tissue confirms a significant increase in pro-survival kinases extracellular-signal regulated kinase and SMAD and a reduction in pro-inflammatory kinases p38 and c-Jun N-terminal kinase in BMP-7 treated mice (P < 0.05). Overall, this study suggests that clodronate treatment inhibits BMP-7 induced differentiation of monocytes into M2 macrophages and improved systolic blood velocity. (Translational Research 2019; 203:1À14) Abbreviations: ApoE = apolipoprotein E; ATH = atherosclerosis; AU = arbitrary units; BMP-7 = bone morphogenetic protein 7; CD206 = cluster of differentiation 206; ELISA = enzyme-linked immunosorbent assay; H&E = hematoxylin & eosin; IV = intravenous; LCA = left carotid artery; LC = liposomal clodronate; LDL = low density lipoproteins; PFA = paraformaldehyde; PLCA = partial ligated carotid artery; TGF-b = transforming growth factor-beta
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Background
Atherosclerosis is an inflammatory disease in which lipids, monocytes, and macrophages accumulate along the endothelial lining leading to arterial plaque formation. Monocytes are known to differentiate into 2 subclasses: M1 and M2. M1 macrophages promote atherosclerosis, whereas M2 macrophages have anti-inflammatory functions which could inhibit plaque formation. However, the current study is designed to understand whether bone morphogenetic protein-7 (BMP-7) enhances M2 macrophage differentiation and reduces plaque formation.
Translational Significance
Our data shows that BMP-7 inhibits monocytes and M1 macrophages, and increases differentiation into M2 macrophages mediated through cJun N-terminal kinase and p38 cell signaling in mid-stage (Day 28) atherosclerosis. Therefore, BMP-7 could have significant translational value in prevention or management of atherosclerosis.
INTRODUCTION
Atherosclerosis (ATH) is an inflammatory disease characterized by lipid, immune cell, and extracellular matrix accumulation within the arterial wall, causing thickening of the affected arterial area. Despite pharmacological interventions, ATH still leads to development of more serious complications, such as heart disease and stroke; two leading causes of death worldwide. 1 ATH is initiated when endothelial cells lining the interior of the artery become irritated as a result of proinflammatory conditions such as dyslipidemia, smoking, hypertension, or disturbances to blood flow. [2] [3] [4] The inflamed endothelium expresses adhesion molecules capable of capturing circulating immune cells, such as monocytes, T cells, and dendritic cells at the area of injury, leading to their subsequent infiltration into the arterial wall. 5 Of research interest, monocytes within the arterial wall are then signaled via cytokines and other molecules, such as low density lipoproteins, to differentiate into macrophages of varying phenotypes, specifically proinflammatory M1 macrophages or anti-inflammatory M2 macrophages. 5 Inflammatory M1 macrophages exhibit a proatherogenic profile, characterized by the release of inflammatory cytokines and activation of pro-inflammatory pathways c-Jun N-terminal kinase (JNK) and p38. 6 Increased M1 macrophage presence is found in cases of severe ATH and these cells are thought to contribute significantly to the advancement of the disease. 6 Additionally, M1 activation of the JNK or p38 pathway in the context of ATH further leads to production of more inflammatory cytokines, fueling the ongoing immune response. 6 Alternatively, monocytes can also differentiate into anti-inflammatory M2 macrophages. M2 macrophages promote clearing of debris and apoptotic cells within the plaque, releasing anti-inflammatory molecules such as interleukin(IL)-10 and IL-4, and aiding in overall suppression of the ongoing immune response. 6 The corresponding balance of the two macrophage phenotypes contributes significantly to plaque progression and disease development. 2, 7, 8 As such, research interest has developed to identify novel, small molecules with the capacity to direct monocyte differentiation to M2 macrophages. Moreover, identification of molecular mechanisms responsible for directing monocyte differentiation to M2 macrophages in vivo remain unclear.
There are a few distinct subsets of M2 macrophages, most notable are M2a and M2c. 6 M2a macrophages have been found to have wound healing and profibrotic properties, and are induced by IL-4 and IL-13. 6, 9, 10 M2c are considered to play a more regulatory role in the disease progression, and these are polarized by IL-10, transforming growth factor-beta (TGF-b), and glucocorticoids. 6, 10 However, the exact molecular mechanisms of these subsets and their specific roles within the differing models of ATH have yet to be fully elucidated. The current study focuses on M2 macrophages as a whole, rather than specific subsets.
Previously, we have shown that treatment with bone morphogenetic protein-7 (BMP-7), a growth factor and member of the TGF-b superfamily, increases the ratio of M2:M1 macrophages in vivo at an early stage of ATH (Day 14). [9] [10] [11] Specifically, BMP-7 treatment directs monocyte polarization towards the anti-inflammatory M2 phenotype and decreases ATH development at an earlier stage. However, it remains unknown as to whether BMP-7 attenuates ATH later in the disease progression, and what the molecular mechanisms are that decrease disease progression once developed. This study was designed to examine the effects of BMP-7 on mid-stage disease development of ATH at a day 28 (D28) time point in Apolipoprotein E (ApoE) knockout (KO) mice which were at least 10 weeks of age, thereby expanding upon the results our previous D14 study that examined early stage ATH. 12 Moreover, we also provide evidence of the involvement of molecular mechanisms mediated through the P38 and JNK pathways leading to increased differentiation of M2 macrophages. Furthermore, we performed additional confirmation by depleting monocytes or M1 macrophages at least partially with liposomal clodronate (LC) to understand whether BMP-7 induces monocyte or M1 macrophage differentiation into M2 macrophages that play a role in improvement of ATH.
MATERIALS AND METHODS
Partial ligated carotid artery (PLCA) surgery. The animal protocol used in the current study was approved by the University of Central Florida Institutional Animal Care and Use Committee (IACUC) and surgery was performed as previously reported. 13 Briefly, 10À12 week old male and female ApoE KO mice were sedated under 3%À4% inhalatory isoflurane and arranged in the supine position. Animals were then divided into 5 groups: (1) Sham, (2) PLCA, (3) PLCA + BMP-7, (4) PLCA+ LC, and (5) PLCA + BMP-7 + LC and administered pain medication via intramuscular injection to the left thigh. Using medical grade scissors and tweezers, the left carotid artery (LCA) was exposed as previously reported. 13 A 7/0 polypropylene or silk suture (CP Medical, #8703P or Ethicon, #768) was then placed around 3 of the 4 branches of the carotid artery; the left external and internal carotid, and the occipital artery. The superior thyroid artery was left undisturbed. After ligation of the artery, the surgical area was closed using a 4/0 silk or polypropylene suture (Ethicon, #736G or CP Medical, #8629) and mice were allowed to recover under oxygen administration via nose cone on a heated pad. Sham animals underwent all of the aforementioned procedure, however, instead of ligating the artery, the suture was simply looped around it but not tied. Following surgery, treatment groups receiving BMP-7 were administered a dose of 200 mg/kg of body weight via tail vein injection (Fig 1) (Bioclone, PA-0401). The BMP-7 injection was repeated 2 more times, at D1 and D2 postsurgery for a total of 3 injections. Groups receiving LC were administered an initial intravenous dose of 200 ml LC immediately following surgery, and subsequent intravenous doses of 100 ml LC every 4 days (Fig 1) , in order to maintain depletion of monocyte and macrophage immune populations for the duration of the D28 time point (Liposoma, LIP-01).
14 Noticeably, LC is reported to have a mortality rate of approximately 33.3% when injected intravenously. 15 In the current study, we faced similar challenges with mortality in mice receiving LC. At the beginning of the study, there was n = 6 mice in both groups receiving LC; however, n = 4 per group survived. Moreover, at D28 postsurgery, systolic blood velocity was examined using carotid artery ultrasound. Upon completion of the ultrasound, animals were sacrificed, blood was collected, and arterial tissue harvested for further analysis. The removed arterial tissue was then divided and placed in either 4% paraformaldehyde for immunohistochemical analysis or RNAlater for Western blot analysis. Once arterial sections incubated for at least 24 hours in 4% paraformaldehyde, they were washed in 1X phosphate-buffered saline and processed overnight using a tissue processor machine (Leica, #15053). The arterial tissue was embedded in a paraffin block with the artery placed vertically upright. The blocks were then sectioned into 5 mm slices and mounted on a charged glass slide (Fisher Scientific, USA). Following heat fixation, slides were deparaffinized using xylene and hydrated using a series of decreasing alcohol dilutions as previously described. 16 This process was performed on arterial sections at various tissue depths from each animal in preparation for hematoxylin and eosin (H&E) staining. The LCA was imaged on the 20X objective using an Olympic IX-70 microscope. Plaque accumulation within the artery was quantified using Image J software as previously described. 13 Immunohistochemistry. Arterial sections were deparaffinized and hydrated as described above. Slides were blocked for 1 hour using 10% goat (Vector, S-1000) or donkey serum (Sigma Aldrich, D9663). After blocking, slides were incubated overnight at 4C with a 1:50 dilution of primary antibody in 10% goat or donkey serum. Primary antibodies used were against cluster of differentiation 14 (CD14) (monocytes, Abbiotec 251561),inducible nitric oxide synthase (iNOS) (M1 macrophages, Abcam, ab15323), CD206 (M2 macrophages, Abcam, ab64693), or Arginase-1 (M2 macrophages, Santa Cruz, sc18351). After overnight incubation, slides were washed and incubated with 1:50 concentration of the appropriate secondary antibody, either Alexa Fluor 488 (Alexa Fluor, A11055 and A11008) for green or 568 (Alexa Fluor, A11011) for red fluorescence, in 1X phosphate-buffered saline for 1 hour at room temperature. Slides were washed and mounted using 4', 6-diamidino-2-phenylindole (DAPI) (Vector Labs). Images of the LCA were taken using the 20X objective on the Olympic IX-70 microscope under fluorescent settings. The %-positive cells for CD14, iNOS, CD206, or Arginase-1 was determined as previously described using ImageJ software (total positive cells/ total nuclei *100). 10 Representative images of each stain were taken using a Leica confocal microscope on the 40X objective.
Pro and anti-inflammatory cytokine analysis of blood serum. Blood serum used for enzyme-linked immunosorbent assay (ELISA) was collected in an ethylenediaminetetraacetic acid containing tube immediately postsacrifice and centrifuged at 12,000 G for 10 minutes. After centrifugation, the supernatant was obtained and stored at 4˚C orÀ20˚C until analysis. Serum ELISAs were performed as previously reported. 10 Proinflammatory serum cytokine levels of IL-6 (RayBiotech, ELM-IL6), monocyte chemoattractant protein(MCP)-1 (RayBiotech, ELM-MCP-1-001), and tumor necrosis factor-a (TNF-a) (RayBiotech, ELM-TNF-a-001) and anti-inflammatory serum cytokine levels of IL-10 (RayBiotech, ELM-IL10-001) and IL-1RA (ELM-IL1RA-001) were evaluated. Serum samples were added to an antibody coated 96-well plate in duplicate and a colorimetric assay performed. Following stoppage of the colorimetric reaction, the samples were read at 450 nm on a microplate reader (BioRad) and graphed in arbitrary units (AU).
Western blot analysis of arterial tissue. Expression of activated pro-inflammatory (p38 and JNK) and antiinflammatory proteins (extracellular-signal regulated kinase [ERK], SMAD) was determined using our standard Western blot technique. 17 In brief, arterial tissue was collected, preserved in RNAlater, and stored at À80˚C until homogenization. Posthomogenization, proteins were estimated using Bradford Assay. Proteins were then analyzed using 10% SDS-PAGE gel electrophoresis and transferred onto a polyvinylidene fluoride membrane (Bio-Rad) using a Bio-Rad Semi-Dry Transfer Cell at 15V for 45 minutes. Membranes were blocked for 1 hour at room temperature with 5% milk, decanted, and incubated overnight with the appropriate primary antibody in 5% milk: p-JNK (Cell Signaling, 1:1000, #4668S), Total JNK (Cell Signaling, 1:1000, #9252S), p-p38 (Cell Signaling, 1:1000, #4631S), Total p38 (Cell Signaling, 1:1000, #9212S), p-ERK (Santa Cruz, 1:1000, sc7383), b-actin (1:1000, Cell Signaling, #4967L) or p-SMAD (Cell Signaling, 1:1000, #13820S). After overnight incubation, membranes were washed and incubated with horseradish peroxidase-conjugated antirabbit IgG (Cell Signaling, 1:1000, #7074S) or antimouse IgG (Santa Cruz, 1:1000, sc2064) for 1 hour at room temperature. Membranes were washed and incubated with enhanced chemiluminescent substrate (Thermo Scientific, #32106). Densitometry analysis of protein expression was completed using Image J as previously reported. 9 Levels of BMP-7 in atherosclerosis. Serum BMP-7 levels (TSZ Scientific, M7485) were examined via ELISA to determine the effect of the diseased state on normal BMP-7 expression. The kit was followed per the manufacturer's protocol on serum samples collected immediately postsacrifice. Analysis of samples was performed on a microplate reader (BioRad) at 450 nm and data plotted as AU.
Systolic blood velocity. Systolic velocity through the carotid artery was acquired using a Phillips Sonos 5500 Ultrasound system at D28 postsurgery. Animals were first sedated at 3% isoflurane/2.5% oxygen and then 2% isoflurane/2.5% oxygen via nose cone and placed in the supine position on a heated pad. Two dimensional (2D) images were then taken (3 per animal) in B mode of blood flow through the LCA. Utilizing the vascular settings, the peak systolic velocity (SV; cm/s) was measured. The average systolic blood velocity was determined utilizing an automated caliper tool within the Sonos 5500 Ultrasound software. Three frames of systolic blood velocity were collected and analyzed for each animal within each treatment group. The frames were subjected to 5 measurements each using the caliper tool, which allowed for a determination of an average SV for each animal. The average SV for each treatment group was determined by combining the individual animal averages into a final representative average.
Statistical analysis of results. All data was analyzed using one-way analysis of variance and the Tukey test. Significance was assigned only if P < 0.05, data is presented as § SEM.
RESULTS BMP-7 attenuates plaque progression. H&E staining was performed on carotid artery sections to determine the extent of plaque formation in animals post-PLCA surgery (Fig 2 AÀE) . Quantitative analysis of the arterial plaque-area resulted in a significant increase in total plaque development in the PLCA group compared to sham (P < 0.05) (Fig 2 F) . Upon treatment with BMP-7, the plaque area is significantly reduced compared to PLCA (P < 0.05). LC administration was unable to provide any reduction compared to the PLCA group; however, in the PLCA + BMP-7 + LC group, the protective effects of BMP-7 on plaque formation are reversed, suggesting that this protective process is mediated through differentiated M2 macrophages (P < 0.05).
Monocyte infiltration into the carotid artery. Initial injury to the arterial endothelium following PLCA surgery results in the recruitment of immune cells to the area of injury, which then infiltrate the artery. 12 Monocytes were one among the most major cell types that infiltrated into the artery and were identified using the antibody against their characteristic marker, CD14. Representative images of CD14-stained monocytes within the LCA are shown in Fig 3A in red (a, e, i, m, q) , DAPI stained nuclei in blue (b, f, j, n, r), and merged images (c, g, k, o, s). An enlarged section of merged images is shown in micrographs d, h, l, p, and t. Quantitative analysis of CD14 +ve monocytes, shown in Fig 3B, were significantly increased in the PLCA group compared to sham animals (P < 0.05). Upon administration of BMP-7, the number of CD14 +ve monocytes was significantly reduced compared to PLCA (P < 0.05). Treatment of LC diminished the arterial monocyte population significantly relative to PLCA and PLCA + BMP-7 (P < 0.05). Notably, the PLCA + BMP-7 + LC demonstrated a decrease in monocytes compared to PLCA + BMP-7; however, data was not statistically significant. Interestingly, this data suggests that LC decreased or diminished monocytes in these groups. Therefore, BMP-7 was unable to differentiate monocytes into M2 macrophages in the left carotid artery, suggesting protective effects of BMP-7 cannot be maintained.
Effect of BMP-7 on M1 macrophages in atherosclerosis. Monocytes present within the subendothelial space of the artery differentiate towards an inflammatory M1 or anti-inflammatory M2 macrophage phenotype contingent on cues received from the cellular microenvironment. 18 In order to evaluate BMP-7's potential to direct monocyte differentiation, LCA sections were stained with an antibody against iNOS, a protein expressed on the surface of M1 macrophages. 8 Representative photos of iNOS-stained sections (Fig 4A) are shown in green (a, e, i, m, q), DAPI stained nuclei in blue (b, f, j, n, r), merged images (c, g, k, o, s) and enlarged sections of merged images (d, h, l, p, t). Quantitative analysis showed a statistically significant increase in iNOS +ve M1 macrophages at D28 postsurgery compared to sham ( Fig 4B) (P < 0.05). Noticeably, BMP-7 treatment significantly reduced the number of proinflammatory M1 macrophages in the injured area vs PLCA (P < 0.05). LC administration resulted in a significant decrease in the presence of iNOS +ve M1 macrophages compared to PLCA, suggesting that LC depleted the M1 macrophages in the artery (P < 0.05). A further decrease in proinflammatory M1 macrophages was seen in the PLCA + BMP-7 + LC group, compared to the PLCA + BMP-7 group. This suggests that the protective effects of BMP-7, via polarization of M1 into M2 macrophages, are not observed with administration of LC.
Effect of BMP-7 on M2 macrophages in atherosclerosis. The ability of BMP-7 to direct monocyte differentiation or M1 macrophage polarization towards the anti-inflammatory M2 phenotype was also evaluated, using an antibody against the characteristic M2 marker, CD206. Representative photos are shown in Fig 5A with CD206 stained in  red (a, e, I , m, q), DAPI stained nuclei in blue (b, f, j, n, r), merged images of CD206 and DAPI (c, g, k, o, s), and enlarged areas of merged images shown (d, h, l, p, t). Quantitative analysis of merged images determined the PLCA group had significantly less antiinflammatory M2 macrophages present in the artery compared to sham (Fig 5B) . Interestingly, BMP-7 treatment following PLCA surgery significantly increased the presence of CD206 +ve anti-inflammatory M2 macrophages within the arterial area (P < 0.05). Administration of LC diminished the presence of CD206 +ve M2 macrophages, relative to sham and PLCA + BMP-7 (P < 0.05). Moreover, in the PLCA + BMP-7 + LC group, there was also a significant decrease in M2 macrophages compared to both sham and PLCA + BMP-7 (P < 0.05). This suggests that differentiated M2 macrophages are also depleted in the artery, as they were unable to polarize or differentiate from M1 macrophages or monocytes, due to depletion with LC. To corroborate the results of the CD206 stain, LCA sections were also analyzed for an additional M2 macrophage marker, arginase-1. 8, 18 The results shown in Fig 6A present arginase-1 stained in green (a, e, i, m, q), DAPI stained nuclei in blue (b, f, j, n, r), merged images of DAPI and arginase-1 (c, g, k, o, s), and selected enlarged areas of merged images (d, h, l, p, t). Quantitative analysis of arginase-1 +ve cells in Fig 6B determined PLCA animals had significantly less M2 macrophages present within the arterial area compared with sham animals. Treatment with BMP-7 following PLCA surgery significantly increased arginase-1 +ve anti-inflammatory M2 macrophages within the arterial area, (P < 0.05). In the PLCA + LC group, there was a significantly diminished presence of arginase-1 +ve cells compared to sham and PLCA+BMP-7 groups (P < 0.05). Moreover, there was also a depletion of M2 macrophages seen in the PLCA + BMP-7 + LC group (P < 0.05). Data from this arginase-1 staining is in agreement with CD206 +ve M2 macrophage staining.
BMP-7 reduces proinflammatory cytokines. M1 macrophages have a characteristic cytokine profile indicative of their inflammatory nature. 6, 8, 18 As such, we evaluated expression of proinflammatory cytokines IL-6, TNF-a, and MCP-1 in blood samples in Fig 7AÀC, respectively. Our ELISA data shows increased levels of IL-6 (P < 0.05), TNF-a, and MCP-1 (P < 0.05) in the PLCA group compared with sham. BMP-7 treated animals had significantly less IL-6, TNFa, and MCP-1 compared to the PLCA animals (P < 0.05). These results support the immunohistochemical findings of reduced M1 macrophage presence in the left carotid arterial area following BMP-7 treatment (Fig 4) .
BMP-7 increases anti-inflammatory cytokines. Blood samples were also assessed using standard ELISA technique for the characteristic anti-inflammatory cytokines IL-10 and IL-1RA released by M2 macrophages 6, 8, 18 ( Fig 8A and B) . PLCA group showed reduced IL-10 levels, though it was not significant to the sham group. However, there was a significant increase in IL-10 in the BMP-7 treated group compared to untreated PLCA group (P < 0.05). Moreover, IL-1RA levels were significantly less in PLCA group compared to the sham. BMP-7 treatment increased IL-1RA levels, but the increase was not statistically significant compared to PLCA group (P < 0.05).
BMP-7 decreases expression of proinflammatory kinases. Cell signaling proteins p38 and JNK are activated in response to inflammatory stimuli in macrophages. 19 To evaluate whether BMP-7 influences p38 and/or JNK activation, western blot analysis of arterial tissue was performed (Fig 9 A and B) . Our western blot analysis showed phosphorylated p38 and JNK were significantly increased in the PLCA group compared to the sham group. Furthermore, PLCA +BMP-7 group exhibited significantly decreased p-p38 and p-JNK compared to the PLCA group, suggesting a potential signaling role in BMP-7 mediated decrease of ATH (P < 0.05).
BMP-7 upregulates SMAD and ERK pathways. Previous in vitro work in our lab showed that upregulation of SMAD transcription factors may play a role in monocyte to M2 macrophage differentiation. 9 Elsewhere, extracellular signal-regulated kinase (ERK) has been shown to play a role in cell proliferation, differentiation, and growth. 20 To evaluate whether BMP-7 regulates ATH progression through SMAD and ERK activity, additional western blot analysis of arterial tissues was performed (Fig 10 A and B) . Phosphorylated SMAD and ERK were both significantly lower (P < 0.05) in PLCA compared to the sham group. However, treatment with BMP-7 increased both p-SMAD and p-ERK (P < 0.05) activation compared to PLCA group.
Progression of atherosclerosis decreases circulating levels of BMP-7. The effect of atherosclerosis on circulating BMP-7 is unknown in ApoE KO animals, and thus was assessed via ELISA (Fig 11) . Results of analysis of blood serum samples showed PLCA group had significantly less BMP-7 present in their blood at D28 postsurgery compared to the sham animals. Furthermore, the BMP-7 group had significantly increased BMP-7 in circulation at D28 postsurgery compared to PLCA animals, suggesting BMP-7 is a key player in ATH development and/or the progression of the disease.
BMP-7 improves systolic blood velocity through the carotid artery. Plaque accumulation within the artery is known to decrease blood flow through the artery. 21 To determine whether BMP-7 treatment affects systolic blood velocity through the arterial region, we performed ultrasound imaging of the LCA in B mode on D28 postsurgery (Fig 12A) . Analysis of systolic velocity showed significant decrease in the PLCA group compared to the sham group (Fig 12B) . Moreover, BMP-7 treatment significantly (P < 0.05) improved systolic blood velocity compared to the PLCA group. PLCA + LC resulted in decreased systolic blood velocity compared to both sham and PLCA+BMP-7. Interestingly, in the PLCA + BMP-7 +LC group, the systolic blood velocity also was significantly decreased compared to sham and PLCA + BMP-7 (P < 0.05). This data indicates that BMP-7 has a beneficial effect in improving systolic blood velocity; however, these beneficial effects of BMP-7 are inhibited with administration of LC.
DISCUSSION
Monocyte polarization into the varied macrophage phenotypes such as M1 or M2 is an active area of investigation. 10 Classically-activated M1 macrophages accumulate in regions of advanced atherosclerosis, release inflammatory cytokines, and enhance the ongoing inflammatory response. 10 While the M1 phenotype enhances the inflammatory response and contributes to plaque accumulation and development, the alternatively activated M2 phenotype releases anti-inflammatory cytokines, continues to engulf and oxidize fatty acids, and aids in moderating the immune response. 6, 8, 18, [22] [23] [24] This current paper investigated how BMP-7, a member of the TGF-b superfamily, alters monocyte differentiation and subsequent contribution to atherosclerotic progression within the carotid artery at a mid-stage (D28) of the disease.
Assessment of plaque accumulation utilizing the H&E stain on carotid artery sections revealed that animals who received tail vein injections of BMP-7 had significantly less plaque within the artery compared to the PLCA group. This finding is in accordance with previous work published by our lab, which found that ApoE KO mice treated with BMP-7 had significantly less plaque present at D14 postsurgery compared to untreated animals. 10 The H&E stain allows for morphological analysis of the arterial area, however it does not specify cell-type within plaque. As previously published by us and others, one of the first cell types to arrive at the area of injury are monocytes. 2 We therefore hypothesized that BMP-7 may reduce plaque development by preventing monocytic recruitment and attachment to the endothelium or prevention of monocytic entry into the subendothelial space postattachment. Our data shows a significant reduction in presence of monocytes in the PLCA group following BMP-7 treatment.
It is possible that BMP-7 works through an alternative method to slow ATH development in the carotid artery, such as monocyte differentiation into M2 macrophages or by reducing the number of M1 macrophages. Therefore, our quantitative analysis showed that PLCA sections had significantly more proinflammatory M1 macrophages. M1 macrophages promote atherogenesis through inflammatory cytokine release and T cell activation. 25, 26 Furthermore, M1 macrophages release of iNOS generates free radicals linked to DNA damage and cellular inflammation 27 . These cells are found to heavily populate advanced plaques. 25, 26 Our data on increased number of M1 Macrophages in atherosclerosis are in agreement with other published studies. 25, 26 Our data shows that BMP-7 reduces plaque formation by differentiating monocytes or M1 macrophages into anti-inflammatory M2 macrophages; however, this does not establish a causal relationship as to whether monocytes or M1 macrophages are truly key players in this process. Therefore we used LC-a macrophage depleting agent -in the present study to demonstrate this relationship. Noticeably, our data shows significant decrease in monocytes and M1 macrophages in the groups treated with LC ( Fig. 3 and 4) . BMP-7 was also unable to differentiate monocytes or M1 macrophages into M2 macrophages in LC treated groups ( Fig. 5 and  6 ). This decrease in immune cell population (M2 macrophages) in LC animals abolished protective effects provided by BMP-7. Moreover, BMP-7 provided significant decrease in plaque formation and improved systolic blood velocity compared to PLCA. However, PLCA + LC treated animals showed a decrease of plaque area, but data was not statistically significant, making it reasonable to state that other cell types, such as vascular smooth muscle cells, foam cells, or immune cells other than monocytes and macrophages, are responsible for the nonsignificant decrease in plaque observed in mice treated with LC versus the PLCA-only group. On the other hand, this decrease in plaque formation and improved systolic blood velocity were reversed when BMP-7 treated animals were also administered LC, suggesting that M2 macrophages are involved in the healing process. Our data is consistent with a previously published report that suggests clodronate depleted macrophages reduces neointimal formation in rats and rabbits. 28 Additionally, depletion of these cell types is consistent with previously published studies which show depletion of monocytes and macrophages in other disease models, such as melanoma, viral encephalitis, and Parkinson's disease. [29] [30] [31] [32] [33] [34] [35] Therefore, we conclude that at least partially, BMP-7 increases M2 differentiation that improves plaque formation and systolic blood velocity function at D28 in ATH. Further studies with CCR2 KO mice and/or mouse models knocking out other cell types are needed to establish which cell population(s), in addition to monocytes and M1 macrophages, are involved in plaque development.
M1 macrophages release inflammatory cytokines such as TNF-a, IL-6, and the monocyte chemoattractant MCP-1. 7, 18, 36 Proatherogenic stimuli IL-6 and TNF-a released from M1 macrophages exacerbate the immune response by triggering apoptosis of surrounding cells and immune cell recruitment. 8, 18, 24 MCP-1 is an important chemoattractant secreted by M1 macrophages to recruit additional monocytes to the area of inflammation. 7 Our blood serum data showed significant increases in proinflammatory cytokines TNF-a, IL-6, and MCP-1, suggesting presence of M1 macrophage and released cytokines in PLCA model. Furthermore, treatment with BMP-7 significantly reduced all three proinflammatory cytokines characteristic of M1 macrophages compared to PLCA animals. Collective immunohistochemical and cytokine ELISA data suggest a reduction in inflammation by BMP-7 treatment.
Unlike M1 macrophages, anti-inflammatory M2 macrophages are found in regressing plaques and shown to prevent progression of atherosclerosis in human and mouse models through modulation of the immune response. 8, 18 M2 macrophages release antiinflammatory cytokines that interfere with the inflammatory action of M1 macrophages. 18, 24, 37 Our immunohistochemical data showed BMP-7 treatment post-PLCA surgery demonstrated upregulation of M2 macrophages. Similarly, M2 macrophages also have a well-characterized and distinct cytokine profile separate from M1 macrophages. IL-10 has been shown to differentiate monocytes in vitro towards the antiinflammatory macrophage phenotype and promote efficient clearing of apoptosed cells in vivo. 18, 24, 37 The significant increase in circulating IL-10 in PLCA + BMP-7 animals compared to the PLCA further confirms the immunohistochemical findings of increased M2 macrophage presence within the atherosclerotic region of the carotid artery. BMP-7 treatment also showed a nonsignificant increase in IL-1RA, an antagonist to the IL-1 receptor, thereby preventing an inflammatory response as a result of a cellular interaction with inflammatory cytokine IL-1. 38 Taken together, these results suggest BMP-7 is capable of directing monocyte or M1 macrophages into antiinflammatory M2 phenotype resulting in reduced ATH in the carotid artery of ApoE KO mice.
To determine if the significant increase in proinflammatory cytokines and increased inflammatory cells had any effect on levels of circulating BMP-7, ELISA was performed. PLCA group showed significantly reduced levels of circulating BMP-7. Moreover, animals that received BMP-7 following ligation of their carotid artery had significantly more BMP-7 in circulation compared to PLCA group. This data indicates that the progression of ATH affects homeostasis of BMP-7. However, further studies are necessary to determine the exact mechanism through which ATH development disturbs BMP-7 production.
To elucidate the mechanism through which BMP-7 promotes monocyte differentiation into M2 macrophages, p38 and JNK cell signaling were evaluated, as these proteins have been linked to inflammation, programmed cell death, and stress response as a result of proinflammatory stimuli. 19, [39] [40] [41] Our data indicates that animals treated with BMP-7 exhibit significantly less activated JNK and p38 compared to PLCA animals at D28. These findings support the immunohistochemical staining indicating a significant reduction in inflammatory M1 macrophages and the ELISA data indicating an overall reduction in inflammatory cytokines of treated animals compared to PLCA. Prosurvival kinase ERK is activated by growth factors and shown to induce cellular proliferation and differentiation. 19, 20 Previous in vitro data published by us suggest that BMP-7 treatment differentiates monocytes into the M2 phenotype mediated through the SMAD 1/5/8 signaling cascade. 9 Our current western blot data of activated SMAD showed a significant increase in the BMP-7 treatment group compared to PLCA animals, suggesting that increased M2/monocyte differentiation is mediated through SMAD signaling cascade in vivo at D28. The SMAD findings in this paper are in agreement with our previously published in vitro data. 9 The methods used in the current paper use indirect methods to analyze the cellular signaling; however, it is possible that this process may also utilize the p38 and JNK pathways due to other cell populations in the affected area. Taken together, our data provide evidences that BMP-7 increases anti-inflammatory M2 macrophage phenotype by decreasing activation of the inflammatory p38 and JNK pathways while activating prosurvival and prodifferentiation kinases ERK and SMAD. Elevation of p-SMAD could also be indicative of TGF-b involvement with the subsets of M2 macrophages such as M2a and M2c, which would be an interesting avenue for a future study. To understand functional significance of BMP-7 treatment, our data shows BMP-7 treatment significantly improved systolic blood velocity compared to PLCA animals and further, that BMP-7's effect on monocyte and macrophage populations is responsible for the observed therapeutic effect.
In future studies, we would like to utilize flow cytometry to isolate specific monocyte/macrophage cell populations and assess their changes across animal study groups. Additionally, it would be interesting to study the effect of BMP-7 administration at D14 postsurgery and determine its therapeutic capabilities on a pre-established plaque. This research plan has a high-value translational application as cases of ATH in humans have pre-established plaques once treatment begins.
In summary, the data in this paper suggest that BMP-7 treated ApoE KO mice have reduced plaque accumulation, decreased proinflammatory cytokines and proinflammatory cells, enhanced differentiation of monocytes into anti-inflammatory M2 macrophages, and improved anti-inflammatory cytokines compared to PLCA animals. We further suggest that increase in M2 macrophages may be mediated through the SMAD and ERK pathways. Further research is necessary to determine if treatment with BMP-7 has a lasting effect on atherosclerosis progression at a chronic stage of the disease.
